Importance of monitoring and early switch to second generation tyrosine kinase inhibitors for the prognosis of patients with chronic myeloid leukemia with imatinib resistance or intolerance
Rev. bras. hematol. hemoter
; Rev. bras. hematol. hemoter;33(1): 65-72, Feb. 2011. tab
Article
in En
| LILACS
| ID: lil-582750
Responsible library:
BR408.1
Localization: BR408.1
ABSTRACT
Imatinib mesylate was the first BCR-ABL-target agent approved for the treatment of chronic myeloid leukemia. Although most patients respond well to imatinib therapy, the literature shows that one third develops resistance or intolerance. The timing of second-line treatment after failure of initial treatment may have a significant impact on long-term outcome. Thus, appropriate monitoring to identify resistance and/or intolerance is crucial to early intervention with second generation tyrosine kinase inhibitors and attainment of better results.
Key words
Full text:
1
Index:
LILACS
Main subject:
Prognosis
/
Pyrimidines
/
Drug Resistance
/
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
/
Environmental Monitoring
/
Drug Monitoring
/
Receptor Protein-Tyrosine Kinases
/
Drug Resistance, Neoplasm
/
Imatinib Mesylate
/
Antineoplastic Agents
Type of study:
Prognostic_studies
Limits:
Humans
Language:
En
Journal:
Rev. bras. hematol. hemoter
/
Rev. bras. hematol. hemoter. (Online)
/
Revista brasileira de hematologia e hemoterapia (Impresso)
Journal subject:
HEMATOLOGIA
Year:
2011
Type:
Article